(Reuters) - GlaxoSmithKline is expected to announce an agreement to acquire Human Genome Sciences for about $2.8 billion as soon as Monday, ending three months of its hostile pursuit of the U.S. biotechnology company, sources familiar with the situation said.
The British pharmaceutical giant is expected to pay around $14 per share, sweetening the offer from its previous $13 per share bid, the sources said. A deal is expected to be announced before the U.S. stock market opens, they said, asking not to be identified because the matter is not public.
http://uk.reuters.com/article/2012/07/16/us-gsk-human-genome-idUKBRE86F00L20120716?rpc=401&feedType=RSS&feedName=innovationNewsHealthcare&rpc=401
2 comments:
Nice post ...thanks for sharing.
very Informative post
Post a Comment